By Raghav Mahobe and Nandhini Srinivasan (Reuters) -Provention Bio Inc has priced its diabetes drug teplizumab at $13,850 a vial, it said on Friday, a day after receiving U.S. approval …
Topic:
provention
-
-
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
by Your News-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022– -Company to host teplizumab commercial launch investor event on …